SCHEMBL5461366

SCHEMBL5461366

COC(=O)c1c(O)cc(C=C2SC(=O)N(Cc3ccc(Cl)cc3Cl)C2=O)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DVL1 O14640 1/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ DNMT1 P26358 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ DUSP3 P51452 1/20 0.47
▸ MCL1 Q07820 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ PTPN1 P18031 2/20 0.46
▸ ACP1 P24666 2/20 0.46
▸ PPARG P37231 5/20 0.45
▸ AKR1B1 P15121 2/20 0.44
▸ AMY1A P0DUB6 2/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ BAG3 O95817 1/20 0.44
▸ ENPP2 Q13822 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461363 1.00 DVL1 (0.49) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5470594 0.90 DVL1 (0.47) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5470591 0.90 DVL1 (0.47) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5461851 0.87 PTPN22 (0.51) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5461849 0.87 PTPN22 (0.51) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5461386 0.86 DVL1 (0.52) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5461388 0.86 DVL1 (0.52) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5454859 0.84 KMT2A (0.56) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5454863 0.84 KMT2A (0.56) DVL1MEN1KMT2AKDM4EALDH1A1
SCHEMBL5465455 0.83 BAG3 (0.54) MEN1KMT2AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 — — US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 DVL1 4062/4885MEN1 2892/4885KMT2A 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback